VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Open Access
- 2 September 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , e1022-e1032
Abstract
Background: VH3810109 (N6LS) is a CD4-binding site antibody with broad and potent neutralizing activity in vitro. Here, we present efficacy, safety, and pharmacokinetic results from the phase 2a BANNER study in people with HIV-1. Methods: BANNER was a randomized, open-label, 2-part, multicenter study of N6LS in adults naive to antiretroviral therapy (ART) with HIV-1 RNA ≥5000 copies/mL. N6LS was evaluated during monotherapy after a single intravenous (IV) infusion at various doses or subcutaneous (SC) injection, followed by 48 weeks of standard-of-care ART. Antiviral activity, safety, pharmacokinetics, and antidrug antibodies (ADAs) were evaluated. Results: Sixty-two participants completed the monotherapy phase and 58 completed the standard-of-care phase. Most participants were male (94%), Hispanic (82%), and White (61%). Virologic response (reduction in HIV-1 RNA ≥0.5 log10 copies/mL from baseline) was achieved in 8/8 (100%; 40 mg/kg IV), 14/15 (93%; 700 mg IV), 5/6 (83%; 280 mg IV), 7/16 (44%; 70 mg IV), and 8/16 (50%; 700 mg SC) participants. Administered IV or SC, N6LS was well tolerated with few drug-related adverse events (n = 13) and no serious adverse events reported during monotherapy. Pharmacokinetic parameters increased proportionally with dose. Incidence of ADAs was dose-dependent and ranged from 6% to 83% in the IV groups; incidence was 19% in the SC group, with no indication that route of administration impacts incidence of ADAs. Conclusions: N6LS was efficacious and generally safe, supporting further development of N6LS dosed IV or SC for the treatment of HIV-1 (ClinicalTrials.gov, NCT04871113).Keywords
Funding Information
- ViiV Healthcare
This publication has 29 references indexed in Scilit:
- Broadly neutralizing monoclonal antibodies for HIV preventionJournal of the International AIDS Society, 2021
- Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsEBioMedicine, 2021
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet HIV, 2019
- Antibody 10-1074 suppresses viremia in HIV-1-infected individualsNature Medicine, 2017
- Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization BreadthImmunity, 2016
- Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?Journal of Allergy and Clinical Immunology, 2015
- Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Nature, 2015
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infectionNature, 2014
- Validation of Accept, a New Generic Measure to Assess How Patients with Chronic Diseases Balance Between the Advantages and Disadvantages of Following the Recommended Treatment Regimen in Real-lifeValue in Health, 2013
- PMC72 DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPSValue in Health, 2009